Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for menâ€™s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patientâ€™s regular Prostate-Specific Antigen (PSA) test.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-21	US$0.8897	-11.03%	369,231
26-07-20	US$1.000	+31.54%	1,094,266
26-07-17	US$0.7602	-3.98%	78,829
26-07-16	US$0.7917	+2.33%	184,835
26-07-15	US$0.7737	-8.84%	342,979

End-of-day quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Nasdaq Other stock markets 2026-07-20			5-day change	1st Jan Change
1.000 ^USD	+31.54%		+17.83%	-98.72%

05-19	Onconetix, Inc. announces 1-for-10 reverse stock split	RE
05-19	Realbotix provides update on Nasdaq listing	RE

Market Cap	3.28M 2.88M 2.67M 2.46M 4.63M 316M 4.69M 31.83M 12.46M 155M 12.33M 12.06M 535M	P/E 2024 *	-	P/E 2025	-0.09x
Enterprise Value	-1.89M -1.65M -1.53M -1.41M -2.66M -182M -2.69M -18.3M -7.16M -89.09M -7.09M -6.93M -308M	EV / Sales 2024	5,556,319x	EV / Sales 2025	-3,367,890x
Free-Float	99.82%	Yield 2024 *	-	Yield 2025	-

05-19	Onconetix, Inc. announces 1-for-10 reverse stock split	RE
05-19	Realbotix provides update on Nasdaq listing	RE
05-13	Onconetix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-24	Onconetix Inc Andrew Oakley resigns as chairman of board	RE
04-24	Onconetix, Inc. Announces Board and Committee Changes	CI
03-31	Onconetix appoints David White as chief executive officer and Sammy Dorf as member of the board of directors	RE
03-24	Onconetix on March 18 appointed David White as CEO, effective as of that date	RE
03-24	Onconetix, Inc. Announces Chief Executive Officer Changes, Effective March 18, 2026	CI
03-24	Onconetix, Inc. Announces Board and Committee Changes, Effective as of March 19, 2026	CI
03-23	Onconetix, Inc. announces 1-for-5 reverse stock split	RE
03-13	Onconetix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-12	Onconetix, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-13	Onconetix, Inc., Realbotix Corp. - M&A Call

23-09-13	Maxim Downgrades Blue Water Biotech to Hold From Buy	MT
23-04-26	HC Wainwright Adjusts Price Target on Blue Water Biotech to $9 From $7, Maintains Buy Rating	MT
22-12-08	Maxim Starts Blue Water Vaccines at Buy With $4 Price Target	MT

Onconetix, Inc. Stock

Stocks

ONCO

US68237Q4010

Pharmaceuticals

Valuation: Onconetix, Inc.

Chart: Onconetix, Inc.

Latest news : Onconetix, Inc.

Last Transcript: Onconetix, Inc.

Analysts' recommendations: Onconetix, Inc.

Press Releases: Onconetix, Inc.

News in other languages: Onconetix, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Onconetix, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

07-07	Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation	AQ
06-24	Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District	AQ
05-19	Onconetix, Inc. Announces 1-for-10 Reverse Stock Split	AQ
05-13	Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study	AQ
04-09	Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson	AQ

1 day	+31.54%
1 week	+17.83%
Current month	-11.50%
1 month	+5.94%
3 months	-85.22%
6 months	-98.75%
Current year	-98.72%

1 week	0.71	1.01
1 month	0.71	1.21
Current year	0.71	115
1 year	0.71	229.5
3 years	0.71	202,247.38
5 years	0.71	1,000,000
10 years	0.71	1,000,000

Manager	Title	Age	Since
David White CEO	Chief Executive Officer	73	2026-03-17
Karina Fedasz CEO	Chief Executive Officer	53	2025-04-01

Director	Title	Age	Since
Joshua Epstein BRD	Director/Board Member	-	2026-04-22
Sarah Romano BRD	Director/Board Member	46	2025-12-04
Sammy Dorf CHM	Chairman	41	2026-04-22

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/14/26	HRT Financial LP	Sell	Company	182,965	26.4047%
4/14/26	HRT Financial LP	Sell	Company	49,710	7.1739%
4/14/26	HRT Financial LP	Other	Company	104,498	15.0807%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCONETIX, INC.	+31.54%	+17.83%	-99.47%	-100.00%	3.28M
REGENERON PHARMACEUTICALS, INC.	+0.45%	+2.91%	+23.77%	-8.09%	68.69B
UCB	+0.41%	+3.86%	+41.87%	+200.66%	52.97B
SAMSUNG BIOLOGICS CO.,LTD.	+3.72%	+39.50%	+39.50%	+39.50%	43.61B
CSL LIMITED	-2.83%	-3.13%	-55.32%	-55.71%	40.75B
BIOGEN INC.	+1.61%	+5.84%	+65.60%	-26.59%	29.99B
MODERNA, INC.	+0.29%	-11.54%	+92.64%	-52.81%	23.67B
INCYTE CORPORATION	+1.50%	+2.18%	+74.22%	+82.99%	23.45B
INNOVENT BIOLOGICS, INC.	+0.11%	-4.95%	+5.31%	+177.86%	20.46B
SWEDISH ORPHAN BIOVITRUM AB	-0.49%	-0.26%	+68.07%	+122.50%	16.66B
Average	+3.59%	+2.66%	+25.62%	+38.03%	32.03B
Weighted average by Cap.	+0.54%	+1.60%	+32.67%	+47.16%

	2024	2025
Net sales	2.52 2.21 2.05 1.89 3.56 243.09 3.6 24.47 9.57 119.13 9.48 9.27 411.35	0.82 0.71 0.66 0.61 1.15 78.53 1.16 7.9 3.09 38.48 3.06 2.99 132.88
Net income	-58.69M -51.44M -47.67M -43.87M -82.73M -5.65B -83.73M -569M -223M -2.77B -220M -216M -9.56B	-14.03M -12.3M -11.4M -10.49M -19.78M -1.35B -20.02M -136M -53.22M -662M -52.67M -51.54M -2.29B
Net Debt	8.8M 7.71M 7.15M 6.58M 12.41M 848M 12.56M 85.31M 33.38M 415M 33.04M 32.33M 1.43B	-5.17M -4.53M -4.2M -3.87M -7.29M -498M -7.38M -50.13M -19.62M -244M -19.41M -19M -843M